Phosphopeptide Neoantigens in Cancer Immunotherapy
Author Information
Author(s): Apoorvi Tyagi, Yury Patskovsky, Iryna Voloshyna, Michelle Krogsgaard
Primary Institution: NYU Grossman School of Medicine
Hypothesis
Phosphorylated peptides (p-peptides) can serve as novel targets for cancer immunotherapy.
Conclusion
Phosphorylated peptides are emerging as a promising class of tumor-specific antigens that could enhance cancer immunotherapy.
Supporting Evidence
- Phosphorylated antigens can enhance tumor immunogenicity and provide multiple immune targets.
- Studies show that p-peptides can be recognized by T cells, leading to anti-tumor responses.
- Immunogenic peptides from phosphorylation represent an untapped class of neoantigens.
Takeaway
Scientists are studying special proteins in cancer cells that have been changed by adding a phosphate group, which can help the immune system recognize and fight cancer better.
Methodology
This review summarizes existing research on phosphopeptide neoantigens and their potential in cancer immunotherapy.
Limitations
Further research is needed to fully understand the role of p-peptides in tumor progression and their immunogenicity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website